

1 **Research Article**

2 **Immunogenomic intertumor heterogeneity across primary and metastatic sites in**
3 **a patient with lung adenocarcinoma**

4 **Authors:** Runzhe Chen^{1,2,#}, Jun Li^{2,#}, Junya Fujimoto³, Xin Hu², Kelly Quek¹, Ming
5 Tang², Akash Mitra², Carmen Behrens¹, Chi-Wan Chow³, Peixin Jiang¹, Latasha D.
6 Little², Curtis Gumbs², Xingzhi Song², Jianhua Zhang², Dongfeng Tan⁴, John V.
7 Heymach¹, Ignacio Wistuba³, P. Andrew Futreal², Don L. Gibbons^{1,*}, Lauren A. Byers^{1,*},
8 Jianjun Zhang^{1,2*}, Alexandre Reuben^{1,*}

9 **Affiliations:**

10 ¹Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD
11 Anderson Cancer Center, Houston, Texas 77030, USA

12 ²Department of Genomic Medicine, the University of Texas MD Anderson Cancer
13 Center, Houston, Texas 77030, USA

14 ³Department of Translational Molecular Pathology, the University of Texas MD
15 Anderson Cancer Center, Houston, Texas 77030, USA

16 ⁴Department of Pathology, the University of Texas MD Anderson Cancer Center,
17 Houston, Texas 77030, USA

18 # co-first authors

19 *Correspondence: dlgibbon@mdanderson.org (D.L.G.), lbyers@mdanderson.org
20 (L.A.B.), jzhang20@mdanderson.org (J.J.Z.), areuben@mdanderson.org (A.R.)

21 **Running title:** Immunogenomic intertumor heterogeneity in lung cancer

22 **Keywords:** lung adenocarcinoma, intertumor heterogeneity, genomic, T cell repertoire

23

24

25 **Abstract**

26 **Background:** Lung cancer is the leading cause of cancer death, partially owing to its
27 extensive heterogeneity. The analysis of intertumor heterogeneity has been limited by
28 an inability to concurrently obtain tissue from synchronous metastases unaltered by
29 multiple prior lines of therapy. **Methods:** In order to study the relationship between
30 genomic, epigenomic and T cell repertoire heterogeneity in a rare autopsy case from a
31 young female never-smoker with late-stage lung adenocarcinoma (LUAD), we did
32 whole-exome sequencing (WES), DNA methylation and T-cell receptor (TCR)
33 sequencing to characterize the immunogenomic landscape of one primary and 19
34 synchronous metastatic tumors. **Results:** We observed heterogeneous mutation,
35 methylation, and T cell patterns across distinct metastases including a set of prevalent T
36 cell clonotypes which were completely excluded from left-side thoracic tumors. Though
37 a limited number of predicted neoantigens were shared, these were associated with
38 homology of the T cell repertoire across metastases. Lastly, ratio of methylated
39 neoantigen coding mutations was negatively associated with T-cell density, richness
40 and clonality, suggesting neoantigen methylation may partially drive
41 immunosuppression. **Conclusions:** Our study demonstrates heterogeneous genomic
42 and T cell profiles across synchronous metastases and how restriction of unique T cell
43 clonotypes within an individual may differentially shape the genomic and epigenomic
44 landscapes of synchronous lung metastases.

45

46 **Background**

47 Lung cancer is the leading cause of cancer death, partially owing to its extensive
48 heterogeneity [1, 2]. It has been proposed that this extensive heterogeneity results from
49 successive clonal expansion and selection of the fittest clones influenced by genomic
50 accumulation and somatic epigenetic alterations [3-6]. However, tumor evolution may
51 also be shaped by pressure from the immune system, which can prune the most
52 immunogenic branches of the tumor [7].

53 T cells play a crucial role in preventing cancer development through antigen-specific
54 detection and destruction of malignant cells, though evolving tumors can eventually
55 escape immune surveillance through a process termed immunoediting [4, 8-11]. Few
56 studies have addressed the impact of the T cell repertoire in shaping metastatic
57 heterogeneity [12-14] with most work to date evaluating longitudinal changes spanning
58 multiple timepoints and therapies. Though these studies offer crucial insights, they do
59 not allow the evaluation of intrinsic intertumor heterogeneity in absence of selective
60 pressure from therapy. Furthermore, to date, the analysis of intertumor heterogeneity
61 has been limited by an inability to concurrently obtain tissue from synchronous
62 metastases unaltered by multiple prior lines of therapy [15-17].

63 Here, we sought to study the relationship between genomic, epigenomic and T cell
64 repertoire heterogeneity in a rare autopsy case from a female never-smoker in her early
65 30s with late-stage lung adenocarcinoma (LUAD) with more than 20 synchronous
66 metastases. We observed heterogeneous mutation, methylation, and T cell patterns
67 across distinct metastases including a set of prevalent T cell clonotypes which were
68 completely excluded from left-side thoracic tumors. Our work further highlights
69 neoantigen methylation as a potential mechanism driving immunosuppression and
70 some of the hurdles facing the treatment of late-stage lung cancer.

71

72 **Methods**

73 **Human subject research**

74 We collected 20 tumor samples and one normal GI sample at autopsy. Collection and
75 use of patient samples were approved by the Institutional Review Board of the
76 University of Texas MD Anderson Cancer Center. Clinical information is presented in
77 **Supplementary Table 1.**

78 **Sample collection**

79 DNA of collected samples was isolated from FFPE tissues using the AllPrep DNA/RNA
80 FFPE Kit (Qiagen, Hilden, Germany). Hematoxylin and eosin (H&E) slides of each case
81 were reviewed by experienced lung cancer pathologists under the microscope to assess
82 the percentage of pre-/micro-invasive neoplastic lesions and tumor tissues versus
83 normal tissues. Tumor cell viability was also assessed by examining the presence of
84 necrosis in the tissues. Only samples with enough viable tumor cells were selected for
85 WES, methylation and immunoSEQ.

86 **DNA preparation**

87 Unstained tissue sections (10 μ m thick) were deparaffinized in xylene and 100% ethanol
88 (twice in each for 10 minutes). The macrodissected tumor areas of the deparaffinized
89 tissues were placed into a 1.5 mL collection tubes for DNA extraction. The tissue was
90 next suspended with Buffer PKD and Proteinase K from the Allprep FFPE kit. After
91 incubating at 56 °C for 15 min then on ice for 5 min, the mixed solution was centrifuged
92 for 15 minutes at 20,000 x g. Finally, the DNA samples were quantified by Nano Drop
93 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The fragmentation
94 sizes were evaluated by the Agilent 2200 Tape Station system using the Genomic DNA
95 Screen Tape Assay (Agilent Technologies, Santa Clara, CA, USA).

96 **Whole-exome sequencing**

97 Exome capture was performed on 500ng of genomic DNA per sample based on KAPA
98 library prep (Kapa Biosystems) using the Agilent SureSelect Human All Exon V4 kit
99 according to the manufacturer's instructions and paired-end multiplex sequencing was
100 performed on the Illumina HiSeq 2000 sequencing platform. The average sequencing
101 depth was 178x (ranging from 63x to 225x, standard deviation +/- 31).

102 **Mutation calling**

103 Tumor contents and major/minor copy number changes were estimated by Sequenza
104 (v2.1.2) [18]. To control those FFPE caused artifact contaminations, somatic single
105 nucleotide variants (SNVs) was first called using MuTect version 1.1.4 [19], VarScan 2
106 [20] and Strelka2 [21] with default setting, respectively. Then, the following filtering
107 criteria were applied to each callers: 1) sequencing depth $\geq 20\times$ in tumor DNA and
108 $\geq 10\times$ in germline DNA; and 2) variant allele frequency (VAF) ≥ 0.02 in tumor DNA and
109 < 0.01 in germline DNA; and 3) the total number of reads supporting the variant calls is
110 ≥ 4 ; and 4) variant frequency is < 0.01 in ESP6500, 1000 genome and EXAC databases;
111 Those mutations called by Mutect with a LOD score < 10 was further filtered out.
112 Those mutations called by Strelka with a quality score below 35 was also filtered out.
113 Finally, only those mutations were kept if called by any of the two tools and rescued if
114 any were rejected but shared by at least two tumors. Identified missense mutations
115 were manually reviewed using the Integrative Genomics Viewer version 2.3.61 [22, 23].

116 **Phylogenetic analysis**

117 Ancestors were germ line DNA assuming with no mutations. The phylogenetic tree was
118 generated as described [24]. A binary presence/absence matrix of all somatic mutations
119 detected was used as input for R package phangorn version 2.0.2 [25].

120 **Neoantigen predictions**

121 Nonsynonymous mutations were identified from WES profiling and the binding affinity
122 with patient-restricted MHC Class I molecules of all possible 9- and 10-mer peptides
123 spanning the nonsynonymous mutations was evaluated with the NetMHC3.4 algorithm
124 based on HLA-A, HLA-B, and HLA-C alleles of each patient [26-28]. Candidate peptides
125 were considered as HLA binders when $IC_{50} < 500$ nM with high affinity binders
126 presenting $IC_{50} < 50$ nM.

127 **DNA methylation profiling and tumor-immune microenvironment deconvolution**

128 Genomic DNA (approximately 500 ng) was bisulfite converted using EZ DNA
129 Methylation Kit (Zymo Research Corp. Irvine, CA, USA) following the manufacturer's
130 protocol. Bisulfite converted DNA materials were then processed and hybridized to the
131 Infinium Human Methylation 450k arrays (Illumina, San Diego, CA, USA) according to
132 manufacturer's recommendation. Preprocessing and initial quality assessments of the
133 raw data were examined using the following R packages. Subset-quantile within-array
134 normalization (SWAN) [29] was used to normalize raw methylation values.
135 IlluminaHumanMethylation450k.db annotation package was used to annotate the CpG
136 probes location. Before any genomics and statistical analyses were conducted, we
137 normalized and inspected the methylation data for the presence of substantial
138 confounding batch effects. Cellular deconvolution analyses were carried out using
139 estimated cellular fractions using MethylCIBERSORT [30].

140 **TCR β sequencing and comparison parameters**

141 Immunosequencing of the CDR3 regions of human TCR β chains was performed using
142 the protocol of immunoSEQ (Adaptive Biotechnologies, hsTCR β Kit) [31-33]. Two sets
143 of PCRs were performed on DNA extracted from the tissues collected. The initial PCR
144 used a mix of multiplexed V- and J-gene primers which amplify all possible recombined
145 receptor sequences from the DNA sample, and then a second PCR designing to add
146 unique DNA barcodes to each PCR product was followed. After that, samples were
147 pooled together with a negative and a positive control. The pools were then sequenced
148 on an Illumina MiSeq platform using 150 cycle paired-end protocol and sequence-ready
149 primers. After finish the sequencing, the raw data were transferred to Adaptive
150 Biotechnologies and processed into a report including those passed quality-check
151 samples and a normalized and annotated TCR β profile repertoire accordingly. Profile of
152 TCR rearrangements is presented in **Supplementary Data**.

153 T-cell density in FFPE tissue samples was calculated by normalizing TCR- β template
154 counts to the total amount of DNA usable for TCR sequencing, where the amount of
155 usable DNA was determined by PCR-amplification and sequencing of housekeeping
156 genes expected to be present in all nucleated cells. T-cell richness is a metric of T cell

157 diversity, and it is calculated by on the T-cell unique rearrangements. T-cell clonality is a
158 metric of T cell proliferation and reactivity, and it is defined as 1-Peilou's evenness.
159 Clonality ranges from 0 to 1: values approaching 0 indicate a very even distribution of
160 frequency of different clones (polyclonal), whereas values approaching 1 indicate a
161 distinct asymmetric distribution in which a few activated clones are present at high
162 frequencies (monoclonal). Statistical analysis was performed in R version 3.2. JI is
163 conceptually a percentage of how many objects of two sets have in common out of how
164 many objects they have in total. $JI = (\text{number of rearrangements in common}) / (\text{total}$
165 $\text{number of rearrangements})$

166 **Statistical Analysis**

167 Graphs were generated with GraphPad Prism 8.0. Spearman's rank correlations were
168 calculated to assess the association between 2 continuous variables. Kruskal-Wallis
169 tests were used for categorical variables with more than 2 levels. P-values less than
170 0.05 were considered to be statistically significant.

171

172 **Results**

173 **Patient information**

174 A female never-smoker in her early 30s presented to her primary care physician
175 complaining of weakness in her upper right arm lasting for two weeks. Physical
176 examination was unremarkable, other than grade 3 weakness in her right upper limb.
177 Shortly after, she was hospitalized due to acute venous thromboembolism of this arm.
178 She was started on anti-coagulants and underwent computed tomography (CT) scans
179 of the chest, abdomen and pelvis and magnetic resonance imaging (MRI) of the brain
180 as part of the work up. Numerous nodules were detected suggestive of extensive
181 metastasis and a 1.9 cm left lung mass was consistent with a lung primary (**Fig. 1a-b**).
182 A liver biopsy revealed the diagnosis of poorly differentiated LUAD. The patient
183 underwent palliative radiation therapy for C5-C7 spine metastases with 10x30 cGy and
184 one dose of chemotherapy with carboplatin and paclitaxel while awaiting molecular

185 profiling results. Her condition deteriorated rapidly and she expired 13 days following
186 her sole dose of chemotherapy. An autopsy was performed and widely disseminated
187 metastatic carcinoma involving multiple systems and organs was observed.

188 To understand the genomic and T cell landscape of this extensively metastatic LUAD,
189 20 tumor samples (**Supplementary Table 1**) including the left lung (primary tumor, P),
190 thyroid gland (M01), left pleural cavity (M02), left hilar lymph node (M03), left-side
191 parietal pleura (M04), heart (M05), right lung (M06), right pleural cavity (M07), 12th
192 thoracic vertebra (M08), gastrointestinal (GI) tract (M09), liver (M10), 4 abdominal lymph
193 nodes (M11-14), left adrenal gland (M15), two metastases in the right kidney (M16 and
194 M17), left and right ovaries (M18 and M19) as well as one histologically normal sample
195 from the GI tract were collected and subjected to whole-exome sequencing (WES),
196 DNA methylation array and T cell receptor (TCR) sequencing.

197 **Distinct mutational profiles are seen across primary tumor and synchronous** 198 **metastases**

199 Overall, 228 non-silent mutations were detected with an average of 76 per sample
200 (range=57-98). The number of non-silent mutations varied between tumors, with only 10
201 shared across all 20 samples (**Fig. 1c**). Of these non-silent mutations, 170 (75%) were
202 shared by at least two tumors while 58 (25%) were unique (**Fig. 1d**). When canonical
203 cancer gene mutations were analyzed[34-36], commonly-mutated cancer genes
204 included TP53, CDKN2A, ASXL1 and MET in this patient (**Supplementary Fig. 1a**).
205 Only TP53 mutation (chromosome 17_7578382, stop gain, spectrum G->C) was
206 detected in all tumors suggesting TP53 mutation was an early genomic event, while
207 other cancer gene mutations were later events which may have followed subclonal
208 diversification. We also constructed a phylogenetic tree to depict the genomic
209 heterogeneity and evolutionary trajectory of these metastatic tumors. As shown in
210 **Supplementary Fig. 1b**, the phylogenetic structure varied considerably between
211 tumors highlighting profound genomic heterogeneity within this patient. We also utilized
212 the Jaccard index (JI), which takes into consideration the proportion of shared non-silent
213 mutations between any two samples. The JI ranged from 0.14 to 0.82 (average=0.49)

214 with more proximal tumors generally more genetically similar (**Supplementary Fig. 1c**).
215 Homology between the primary and metastases ranged from 0.14 to 0.73
216 (average=0.33), with the thoracic lesions including the left pleural metastasis, left hilar
217 lymph node and right pleural metastasis exhibiting the greatest similarity with the
218 primary tumor. Taken together, these results reveal marked genomic heterogeneity
219 across different metastases within the same patient.

220 **The T cell infiltrate in distant metastases is more dense, diverse and reactive**

221 The crucial role of T cells in immunoediting led us to study the T cell repertoire to further
222 investigate the spatial heterogeneity of T-cell responses[37, 38]. T-cell density, an
223 estimate of the fraction of T cells within a tumor, ranged from 3% to 38% (average=13%,
224 **Fig. 2a**), while richness, a measure of T-cell diversity, ranged from 4,168 to 23,487
225 unique T-cell rearrangements (average=14,344 unique rearrangements, **Fig. 2b**). T-cell
226 clonality, a measure of T-cell reactivity, ranged from 0.02 to 0.05 (average=0.04, **Fig.**
227 **2c**). All TCR metrics were positively inter-correlated (Density vs. Richness: $r=0.53$,
228 $p=0.02$; Density vs. Clonality: $r=0.54$, $p=0.02$; Clonality vs. Richness: $r=0.54$, $p=0.01$,
229 **Fig. 2d**). Compared to prior work from our group in an early-stage LUAD cohort[39],
230 lower T-cell density ($p<0.05$) and clonality ($p<0.0001$) and higher richness ($p<0.0001$)
231 were observed in tumors from this patient (**Supplementary Fig. 2a-e**).

232 Tumors were then grouped anatomically. Non-thoracic tumors displayed higher T-cell
233 density ($p<0.01$), richness ($p<0.0001$) and clonality ($p<0.01$) than thoracic tumors
234 (**Supplementary Fig. 3a-c**), perhaps owing to their anatomical location far from the
235 primary tumor which are more likely to escape from immune surveillance[40, 41]. Lymph
236 nodes serve as sites of T cell priming, activation, and modulation, leading us to
237 speculate that the interaction between metastatic cancer cells and T cells in lymph
238 nodes may be distinct compared to other sites of metastases. However, no statistical
239 differences were observed in relation to lymph node involvement (**Supplementary Fig.**
240 **3d-f**). Taken together, these data suggest differences in T cell response based on
241 anatomical site, that is, T cell exclusion, suppression and a more focused T cell
242 response in proximity to the primary tumor.

243 **Distinct TCR repertoire profiles are associated with left-side thoracic tumors**

244 To evaluate T-cell responses in the tumors, we next focused on the most prevalent TCR
245 clonotypes. Distinct clonotypes were detected in left-side thoracic tumors (left lung
246 tumor, left pleural cavity and rib, left pulmonary hilar lymph node and left side parietal
247 pleura) compared to others. Strikingly, the most prevalent clonotype in “other” tumors
248 (*CACRPGNEAFF*) was entirely undetectable in left-side thoracic tumors (P, M02, M03
249 and M04) (**Fig. 2e**). Similar trends were also observed among the top 5 and 10 TCR
250 clonotypes with certain clonotypes completely excluded from left side thoracic tumors
251 (**Supplementary Fig. 4a-b**). These data illustrate spatial restriction even among the
252 most prevalent T cell clonotypes across synchronous metastases.

253 **T-cell repertoire heterogeneity is observed across differentially growing tumors**

254 To gain deeper insights into TCR heterogeneity, we assessed the overlap between T
255 cell repertoires across different tumors. We first compared the proportion (JI) and
256 frequency of T cell clonotypes shared between the primary tumor and metastases. In
257 accordance with the unique T cell clonotype pattern observed in tumors from the left
258 side thorax, proportions and frequencies of shared T cells were much more similar
259 between the three left thoracic metastases (M02, M03 and M04) and primary tumor (P)
260 (**Fig. 3a-c**). T cell repertoire heterogeneity was evident across all tumors, with an
261 average JI value of 0.35 (ranging from 0.12 to 0.61) and more shared T cells between
262 proximal tumors (**Fig. 4a**), significantly higher than in a previously published cohort of
263 11 multi-region localized non-small cell lung cancers[42] (average 0.35 vs. 0.17,
264 $p < 0.0001$) (**Supplementary Fig. 5**). Next, we studied the proportion and frequency of
265 shared T cell clonotypes across all 20 tumors. In total, 599 shared T-cell clones were
266 shared across all tumors, with proportions ranging from 3.0% to 15.4% (average=5.39%)
267 and frequencies accounting for 11.9% to 21.5% of the T cell repertoire
268 (average=15.96%) (**Supplementary Fig. 6a-b**). Of interest, both a greater proportion
269 ($p < 0.01$) and percentage ($p < 0.01$) of shared T cell clones were observed in thoracic
270 tumors compared to non-thoracic tumors (**Supplementary Fig. 6c-d**).

271 **Evolution of synchronous metastases may be shaped by the T cell repertoire**

272 We next performed *in silico* prediction of HLA-A-, -B-, and -C-presented neoantigens
273 using NetMHC3.4[26-28]. On average, 39 predicted neoantigens ($IC_{50} < 500$ nmol/L)
274 were detected per tumor, with the most ($n=60$) seen in the primary tumor and fewest
275 ($n=20$) in the thyroid gland. Only 11 high binding affinity neoantigens were detected on
276 average ($IC_{50} < 50$ nmol/L) with the most ($n=19$) also in the primary tumor and least
277 ($n=2$) in the thyroid gland (**Fig. 5a**). This falls within range but below the average of 53
278 predicted neoantigens seen in non-smokers from TCGA (**Fig. 5b**). We then evaluated
279 the relationship between the T cell repertoire and predicted neoantigens. Predicted
280 neoantigen heterogeneity was also evident, with the average JI value of 0.44 (ranging
281 from 0.11 to 0.84, **Fig. 4b**), and a weak but statistically-significant positive correlation
282 between T-cell repertoire and neoantigen homology ($r=0.12$, $p=0.0162$, **Fig. 4c**), which
283 could suggest the distribution of T cells may be partially driven by their reactivity to
284 shared neoantigens. Interestingly, ratio of methylated neoantigen coding mutations was
285 negatively associated with T-cell density ($r=-0.46$, $p=0.0549$), richness ($r=-0.55$,
286 $p=0.0152$) and clonality ($r=-0.61$, $p=0.0055$) (**Fig. 5c-e**), suggesting neoantigen
287 methylation may contribute to immune suppression and potentially explaining the weak
288 neoantigen associations with T cell repertoire homology.

289 In order to classify the T cell subsets infiltrating the tumor, we next performed cellular
290 deconvolution analyses using MethyICIBERSORT (**Fig. 4d**)[30]. Relative $CD8^+$ T cell
291 fraction but not $CD4^+$ and other immune subsets was proportional to richness ($r=0.75$,
292 $p=0.0002$) and clonality ($r=0.43$, $p=0.063$) (**Fig. 4e-f**). Furthermore, CD8 to Treg ratio,
293 which correlates with a more favorable outcome in cancer[43, 44], was proportional to
294 T-cell richness ($r=0.68$, $p=0.0012$) and clonality ($r=0.64$, $p=0.032$) (**Supplementary Fig.**
295 **7a-b**). A negative correlation between $CD8^+$ T cell fraction and methylated neoantigen
296 coding mutations was also observed ($r=-0.48$, $p=0.0391$, **Fig. 5e**). These results
297 highlight the greater proliferative potential of $CD8^+$ T cells and suggest T cell reactivity
298 and diversity may be mainly driven by the clonal expansion of $CD8^+$ T cells at the
299 patient level, as previously suggested by our group and others in a large cohort of
300 early-stage non-small cell lung cancers[45]. Overall, our findings suggest that the

301 evolution of synchronous metastases may be shaped by the T cell response including in
302 absence of prior therapy.

303

304 **Discussion**

305 Metastasis is an evolutionary process shaped by the dynamic interactions between
306 tumor cells and host factors including immune surveillance [46]. T cells play a pivotal
307 role in mediating this process by recognizing antigens presented on MHC molecules at
308 the surface of tumors and carrying out cytotoxic responses against tumor cells
309 harboring their cognate antigens [47]. Accordingly, much importance has been
310 attributed to T cell infiltration in many solid tumors, with more T cells generally
311 associated with a better prognosis [37, 48, 49]. However, recent studies have
312 highlighted the impact of intratumor heterogeneity and bystander T cells [50-52], and
313 suggested that only ~10% of tumor-infiltrating lymphocytes are capable of recognizing
314 antigens presented by the tumor they have infiltrated [53], prompting deeper
315 investigations into the T cell repertoire. Our understanding of the role of genomic and
316 immune heterogeneity in lung cancer has evolved in recent years, thanks to
317 investigations by our group and others into differences between regions of individual
318 tumors, synchronous metastases and between primary and metastatic tumors [54-58]
319 highlighting potential spatial and temporal factors influencing clinical outcomes [59, 60].
320 Here, we assess the characteristics of the T cell repertoire in a treatment-naïve non-
321 smoking patient with synchronous lung metastases and depict the interplay between the
322 primary tumor and synchronous metastases [11, 55, 61], revealing extensive
323 immunogenomic intertumor heterogeneity across primary and metastatic sites.

324 In our study, clonal *TP53* mutations were detectable in all tumors, suggestive of an early
325 genomic event, in line with prior reports [24, 62]. Interestingly, a higher overlap in
326 somatic mutations was observed across proximal tumors suggesting they are more
327 genetically similar, potentially due to metastatic seeding from the primary tumor [63, 64].
328 Though our study focused on a single patient, the overlap in mutational burden
329 observed between synchronous metastases is in line with previous reports in lung [58],

330 melanoma [65], kidney [66] and colon cancer [67]. Considering the role of somatic
331 mutations in triggering T cell responses through the generation of neoantigens, this
332 overlap suggests these somatic mutations may serve as potential therapeutic targets for
333 vaccination or T cell engineering through targeting of unifying antigens present across
334 all synchronous tumors. This is supported by the modest but significant correlation
335 between shared mutations and shared TCRs though additional studies are needed to
336 confirm these hypotheses.

337 We observed lower T cell repertoire heterogeneity across synchronous metastases in
338 our study than in our prior work assessing multi-region ITH in localized LUAD [55]. This
339 difference could highlight the distinct resistance mechanisms at play in accelerated
340 progression in our study versus more gradual progression in early-stage LUAD which
341 may have allowed for divergent genomic evolution and immune editing over decades.
342 This is reinforced by the absolute restriction of certain T cell clonotypes to metastases
343 surrounding the primary tumor, which could be reflective of the distinct antigenic
344 environments established in distal tumors. Unfortunately, our lack of deep immune
345 phenotyping data precludes our ability to further investigate the role the distinct immune
346 microenvironments, including chemokine gradients and receptors, may have played in
347 establishing these vastly distinct T cell microenvironments. However, the presence of
348 shared T cell clonotypes could also be indicative of common responses against unifying
349 antigens displayed across synchronous metastases.

350 Aberrant methylation is involved in tumorigenesis in a variety of cancers [68, 69] and
351 could affect immune surveillance directly by regulating the expression of immune-
352 related genes and/or potential neoantigens[70]. DNA methylation-induced silencing of
353 genes that encode tumor associated antigens form a complex gene-regulatory network
354 for suppressing anti-tumor immune responses and therefore facilitating immune evasion
355 [71]. Interestingly, in the current study, ratio of methylated neoantigen coding mutations
356 was negatively associated with T-cell density, richness and clonality, even at the
357 individual tumor level. One could therefore hypothesize that therapeutic agents
358 modulating methylation could potentially reprogram the immune microenvironment and
359 could exhibit some potential in treating these tumors.

360 Our study does exhibit certain limitations, including its focus on a single patient.
361 However, analysis of several synchronous tumor sites from a single patient with
362 advanced disease in absence of heavy pre-treatment is rarely possible, mainly due to
363 the lack of clinical indication. Unfortunately, deeper analysis of underlying mechanisms,
364 immune cells and soluble factors influencing T cell trafficking and heterogeneity remain
365 unclear due to the archival nature of these samples and will require further investigation.
366 Despite these limitations, our study provides important evidence of differential tumor-
367 immune responses co-existing in metastases within the same individual, related not
368 only to molecular alterations. As a result, our findings may also partially explain the
369 challenge of treating late-stage lung cancer due to the heterogeneity of metastases.
370 Additional genomic, transcriptomic and immune studies in patients with synchronous
371 metastases could help shed light on these and other mechanisms at play and provide
372 therapeutic insights into late-stage non-small cell lung cancer. Lastly, our findings
373 emphasize the need to obtain multiple biopsies when feasible in patients with multiple
374 synchronous lung tumors as has been suggested in metastatic melanoma, even in
375 absence of selective pressure from therapy. Concurrent analysis of multiple tumors from
376 the same patient could help identify unifying antigens and mechanisms capable of
377 prolonging survival in patients with metastatic lung cancer [65].

378

379 **Conclusion**

380 In summary, in this study, we present the immunogenomic landscape of one primary
381 tumor and 19 synchronous metastases from a minimally-pretreated young female
382 never-smoker with late-stage LUAD. Fewer less diverse and reactive T cells infiltrated
383 the metastases nearest to the primary tumor, and a set of prevalent T cell clonotypes
384 were excluded from left-side thoracic tumors further suggesting immune escape near
385 the primary site. Furthermore, shared predicted neoantigens were associated with
386 homology of the T cell repertoire across metastases. Lastly, ratio of methylated
387 neoantigen coding mutations was negatively associated with T-cell density, richness
388 and clonality, suggesting neoantigen methylation may partially drive

389 immunosuppression. Our study demonstrates heterogeneous genomic and T cell
390 profiles across synchronous metastases and how restriction of unique T cell clonotypes
391 within an individual may differentially shape the genomic and epigenomic landscapes of
392 synchronous lung metastases.

393

394 **Abbreviations**

395 CT: computed tomography

396 H&E: hematoxylin and eosin

397 JI: Jaccard index

398 LUAD: lung adenocarcinoma

399 MRI: magnetic resonance imaging

400 SNVs: single nucleotide variants

401 SWAN: subset-quantile within-array normalization

402 TCR: T cell receptor

403 WES: whole-exome sequencing

404 VAF: variant allele frequency

405

406 **References**

- 407 1. Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, et al. Novel therapeutic
408 targets on the horizon for lung cancer. *The Lancet Oncology*. 2016; 17: e347-e62.
- 409 2. Negrao MV, Quek K, Zhang J, Sepesi B. TRACERx: Tracking tumor evolution to
410 impact the course of lung cancer. *The Journal of thoracic and cardiovascular surgery*.
411 2018; 155: 1199-202.
- 412 3. Nowell PC. The clonal evolution of tumor cell populations. *Science*. 1976; 194:
413 23-8.
- 414 4. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving
415 paradigms. *Cell*. 2011; 147: 275-92.
- 416 5. Yates LR, Campbell PJ. Evolution of the cancer genome. *Nat Rev Genet*. 2012;
417 13: 795-806.

- 418 6. Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, et al. DNA methylation
419 intratumor heterogeneity in localized lung adenocarcinomas. *Oncotarget*. 2017; 8:
420 21994-2002.
- 421 7. Galon J, Bruni D. Tumor Immunology and Tumor Evolution: Intertwined Histories.
422 *Immunity*. 2020; 52: 55-81.
- 423 8. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system
424 during cancer development. *Nature reviews cancer*. 2006; 6: 24-37.
- 425 9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's
426 roles in cancer suppression and promotion. *Science (New York, NY)*. 2011; 331: 1565-
427 70.
- 428 10. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annual*
429 *review of immunology*. 2004; 22: 329-60.
- 430 11. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al.
431 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint
432 blockade. *Science*. 2016; 351: 1463-9.
- 433 12. Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, et al.
434 Evolution of Metastases in Space and Time under Immune Selection. *Cell*. 2018; 175:
435 751-65.e16.
- 436 13. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, et al.
437 Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. *Cell*.
438 2018; 173: 1755-69.e22.
- 439 14. Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et
440 al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing
441 Metastases in an Ovarian Cancer Patient. *Cell*. 2017; 170: 927-38.e20.
- 442 15. Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, et al. The genetic
443 evolution of metastatic uveal melanoma. *Nature genetics*. 2019; 51: 1123-30.
- 444 16. Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, Long GV. Clinical activity
445 of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.
446 *Pigment cell & melanoma research*. 2015; 28: 607.
- 447 17. Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, et al.
448 Phylogenetic analyses of melanoma reveal complex patterns of metastatic
449 dissemination. *Proceedings of the National Academy of Sciences*. 2015; 112: 10995-
450 1000.
- 451 18. Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q, et al.
452 Sequenza: allele-specific copy number and mutation profiles from tumor sequencing
453 data. *Ann Oncol*. 2015; 26: 64-70.
- 454 19. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al.
455 Sensitive detection of somatic point mutations in impure and heterogeneous cancer
456 samples. *Nature biotechnology*. 2013; 31: 213-9.
- 457 20. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2:
458 somatic mutation and copy number alteration discovery in cancer by exome sequencing.
459 *Genome research*. 2012; 22: 568-76.
- 460 21. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Kallberg M, et al. Strelka2:
461 fast and accurate calling of germline and somatic variants. *Nature methods*. 2018; 15:
462 591-4.

- 463 22. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et
464 al. Integrative genomics viewer. *Nature biotechnology*. 2011; 29: 24-6.
- 465 23. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV):
466 high-performance genomics data visualization and exploration. *Briefings in*
467 *bioinformatics*. 2013; 14: 178-92.
- 468 24. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah
469 S, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. *The New England*
470 *journal of medicine*. 2017; 376: 2109-21.
- 471 25. Schliep KP. phangorn: phylogenetic analysis in R. *Bioinformatics (Oxford,*
472 *England)*. 2011; 27: 592-3.
- 473 26. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-
474 3.0: accurate web accessible predictions of human, mouse and monkey MHC class I
475 affinities for peptides of length 8-11. *Nucleic acids research*. 2008; 36: W509-12.
- 476 27. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction
477 of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained
478 on 9mers. *Bioinformatics (Oxford, England)*. 2008; 24: 1397-8.
- 479 28. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, et al.
480 NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and
481 -B locus protein of known sequence. *PloS one*. 2007; 2: e796.
- 482 29. Turker MS. The establishment and maintenance of DNA methylation patterns in
483 mouse somatic cells. *Seminars in cancer biology*. 1999; 9: 329-37.
- 484 30. Chakravarthy A, Furness A, Joshi K, Ghorani E, Ford K, Ward MJ, et al. Pan-
485 cancer deconvolution of tumour composition using DNA methylation. *Nature*
486 *communications*. 2018; 9: 3220.
- 487 31. Robins HS, Campregher PV, Srivastava SK, Wachter A, Turtle CJ, Kahsai O, et
488 al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T
489 cells. *Blood*. 2009; 114: 4099-107.
- 490 32. Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons
491 JM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. *Nature*
492 *communications*. 2013; 4: 2680.
- 493 33. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, et al.
494 Ultra-sensitive detection of rare T cell clones. *Journal of immunological methods*. 2012;
495 375: 14-9.
- 496 34. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al.
497 Somatic mutations affect key pathways in lung adenocarcinoma. *Nature*. 2008; 455:
498 1069-75.
- 499 35. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al.
500 Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell*.
501 2012; 150: 1107-20.
- 502 36. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al.
503 Genomic landscape of non-small cell lung cancer in smokers and never-smokers. *Cell*.
504 2012; 150: 1121-34.
- 505 37. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-
506 1 blockade induces responses by inhibiting adaptive immune resistance. *Nature*. 2014;
507 515: 568-71.

- 508 38. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved
509 survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
510 *Science translational medicine*. 2014; 6: 238ra70.
- 511 39. Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, et al. OA 13.05
512 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell
513 Lung Cancers and Paired Normal Lung Tissues. *Journal of Thoracic Oncology*. 2017;
514 12: S1780.
- 515 40. Gil Del Alcazar CR, Alečković M, Polyak K. Immune Escape during Breast Tumor
516 Progression. *Cancer immunology research*. 2020; 8: 422-7.
- 517 41. Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson A, Czerniecki BJ, et
518 al. Immune interconnectivity of anatomically distant tumors as a potential mediator of
519 systemic responses to local therapy. *Scientific reports*. 2018; 8: 9474.
- 520 42. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu C-J, et al. TCR
521 repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association
522 with predicted neoantigen heterogeneity and postsurgical recurrence. *Cancer discovery*.
523 2017; 7: 1088-97.
- 524 43. Baras AS, Drake C, Liu J-J, Gandhi N, Kates M, Hoque MO, et al. The ratio of
525 CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-
526 based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma
527 of the bladder. *Oncoimmunology*. 2016; 5: e1134412-e.
- 528 44. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al.
529 Human leukocyte antigen class I, MHC class I chain-related molecule A, and
530 CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer
531 patients? *Clinical Cancer Research*. 2008; 14: 2028-35.
- 532 45. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, et al. Diversity and clonal
533 selection in the human T-cell repertoire. *Proceedings of the National Academy of
534 Sciences of the United States of America*. 2014; 111: 13139-44.
- 535 46. Labelle M, Hynes RO. The initial hours of metastasis: the importance of
536 cooperative host-tumor cell interactions during hematogenous dissemination. *Cancer
537 discovery*. 2012; 2: 1091-9.
- 538 47. Kitamura T, Qian B-Z, Pollard JW. Immune cell promotion of metastasis. *Nature
539 Reviews Immunology*. 2015; 15: 73-86.
- 540 48. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4
541 blockade broadens the peripheral T-cell receptor repertoire. *Clinical cancer research :
542 an official journal of the American Association for Cancer Research*. 2014; 20: 2424-32.
- 543 49. Reuben A, Gittelman R, Zhang J, Quek K, Vence LM, Behrens C, et al.
544 Association of the T-cell receptor landscape with survival in non-small cell lung cancer.
545 *Journal of Clinical Oncology*. 2018; 36: 140-.
- 546 50. Chiou S-H, Tseng D, Reuben A, Mallajosyula V, Molina IS, Conley S, et al.
547 Global analysis of shared T cell specificities in human non-small cell lung cancer
548 enables HLA inference and antigen discovery. *Immunity*. 2021; 54: 586-602. e8.
- 549 51. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, et al.
550 Comprehensive T cell repertoire characterization of non-small cell lung cancer. *Nat
551 Commun*. 2020; 11: 603.

- 552 52. Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, et al. Bystander
553 CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.
554 Nature. 2018; 557: 575-9.
- 555 53. Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MA, et al.
556 Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.
557 Nature medicine. 2019; 25: 89-94.
- 558 54. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor
559 heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
560 Science. 2014; 346: 256-9.
- 561 55. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, et al. TCR
562 Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An
563 Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
564 Cancer Discov. 2017; 7: 1088-97.
- 565 56. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, et al. Multiomics
566 profiling of primary lung cancers and distant metastases reveals immunosuppression as
567 a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020; 21:
568 271.
- 569 57. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, et al.
570 Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune
571 Checkpoint Inhibitors in NSCLC. Journal of thoracic oncology : official publication of the
572 International Association for the Study of Lung Cancer. 2020; 15: 1449-59.
- 573 58. Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, et al. Genomic heterogeneity of
574 multiple synchronous lung cancer. Nature communications. 2016; 7: 1-8.
- 575 59. Kim R, Keam B, Kim S, Kim M, Kim SH, Kim JW, et al. Differences in tumor
576 microenvironments between primary lung tumors and brain metastases in lung cancer
577 patients: therapeutic implications for immune checkpoint inhibitors. BMC cancer. 2019;
578 19: 1-10.
- 579 60. Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, et al.
580 Next-generation sequencing reveals high concordance of recurrent somatic alterations
581 between primary tumor and metastases from patients with non-small-cell lung cancer.
582 Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
583 2013; 31: 2167-72.
- 584 61. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor
585 heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
586 Science (New York, NY). 2014; 346: 256-9.
- 587 62. Leong TL, Gayevskiy V, Steinfert DP, De Massy MR, Gonzalez-Rajal A, Marini
588 KD, et al. Deep multi-region whole-genome sequencing reveals heterogeneity and
589 gene-by-environment interactions in treatment-naive, metastatic lung cancer. Oncogene.
590 2019; 38: 1661-75.
- 591 63. Cheung KJ, Ewald AJ. A collective route to metastasis: Seeding by tumor cell
592 clusters. Science. 2016; 352: 167-9.
- 593 64. Heyde A, Reiter JG, Naxerova K, Nowak MA. Consecutive seeding and transfer
594 of genetic diversity in metastasis. Proceedings of the National Academy of Sciences.
595 2019; 116: 14129-37.

- 596 65. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, et al.
597 Genomic and immune heterogeneity are associated with differential responses to
598 therapy in melanoma. *NPJ Genom Med.* 2017; 2.
- 599 66. Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat
600 M, et al. Comparative genomic profiling of matched primary and metastatic tumors in
601 renal cell carcinoma. *European urology focus.* 2018; 4: 986-94.
- 602 67. Lim B, Mun J, Kim JH, Kim CW, Roh SA, Cho DH, et al. Genome-wide mutation
603 profiles of colorectal tumors and associated liver metastases at the exome and
604 transcriptome levels. *Oncotarget.* 2015; 6: 22179-90.
- 605 68. Ehrlich M. DNA hypomethylation in cancer cells. *Epigenomics.* 2009; 1: 239-59.
- 606 69. Park C, Jeong K, Park JH, Jung S, Bae JM, Kim K, et al. Pan-cancer methylation
607 analysis reveals an inverse correlation of tumor immunogenicity with methylation
608 aberrancy. *Cancer immunology, immunotherapy : CII.* 2021; 70: 1605-17.
- 609 70. Rosenthal R, Cadieux EL, Salgado R, Al Bakir M, Moore DA, Hiley CT, et al.
610 Neoantigen-directed immune escape in lung cancer evolution. *Nature.* 2019; 567: 479-
611 85.
- 612 71. Liu M, Zhou J, Chen Z, Cheng AS. Understanding the epigenetic regulation of
613 tumours and their microenvironments: opportunities and problems for epigenetic
614 therapy. *The Journal of pathology.* 2017; 241: 10-24.

615

616

617

618

619

620

621

622

623

624 **Declarations**

625 **Ethics approval**

626 Collection and use of patient samples were approved by the Institutional Review Board
627 of the University of Texas MD Anderson Cancer Center.

628 **Consent for publication**

629 Not applicable

630 **Competing interests**

631 L.A.B. serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio,
632 Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer
633 and has research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology and
634 Tolero Pharmaceuticals. I.W. reports grants and personal fees from Genentech/Roche,
635 Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck,
636 and Guardant Health; personal fees from GlaxoSmithKline and MSD; grants from
637 Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus,
638 Johnson & Johnson, Iovance, 4D, Novartis, Oncocyte and Akoya. J.J.Z. reports
639 research funding from Merck, Johnson and Johnson, and consultant fees from BMS,
640 Johnson and Johnson, AstraZeneca, Geneplus, OrigMed and Innovent outside the
641 submitted work. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim,
642 Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui
643 Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati
644 Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus
645 Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments,
646 Roche and Leads Biolabs. A.R. serves on the Scientific Advisory Board and has
647 received honoraria from Adaptive Biotechnologies. The other authors declare no
648 competing interests.

649 **Author contributions**

650 A.R., D.L.G., L.A.B. and J.J.Z. conceived the study. J.L. and R.C. led the data analysis.
651 J.F, D.T., and C.W.C. led the pathological assessment, multi-region sample preparation
652 and DNA extraction. R.C., K.Q. and M.T. collected resected specimens and clinical data.
653 L.L. and C.G. performed DNA preparation and whole-exome sequencing. X.S. and

654 J.H.Z. performed sequencing raw data processing. J.L., X.H., K.Q., M.T. and A.M.
655 performed downstream bioinformatics analyses. R.C., C.B, P.J., J.V.H., I.W., P.A.F.,
656 D.L.G, L.A.B., J.J.Z. and A.R. interpreted the data for clinical and pathological
657 correlation. R.C. and J.L. performed statistical analyses. R.C., J.J.Z and A.R. wrote the
658 paper. All authors edited the manuscript.

659 **Acknowledgements**

660 This work was supported by Conquer Cancer Foundation ASCO Young Investigator
661 Award, MD Anderson Physician Scientist Award, Cancer Prevention & Research
662 Institute of Texas (CPRIT) Multiple Investigator Award, TJ Martell Foundation, NIH/NCI
663 R01-CA207295, NIH/NCI U01-CA213273 and Department of Defense (LC170171). A.R.
664 is supported by the Exon 20 Group, Rexanna's Foundation for Fighting Lung Cancer,
665 the Waun Ki Hong Lung Cancer Research Fund, MD Anderson's Lung
666 Cancer Moon Shot and the University Cancer Foundation via the Institutional Research
667 Grant program at the University of Texas MD Anderson Cancer Center.

668

669 **Figure legends**

670 **Figure 1. Synchronous metastatic tumors exhibit heterogeneous growth and**
671 **somatic mutation and neoantigen patterns. a)** Anatomical map of representative
672 biospecimen collection sites in the patient. **b)** Representative CT and MRI scans of
673 different resected tumors: primary lung tumor, cervical lymph node enlargement, liver
674 metastasis and C5 spine compression fracture by metastasis. **c)** Non-silent mutation
675 counts in tumors. **d)** Fraction of shared and unique non-silent mutations across tumors.

676 **Figure 2. Characterization of TCR repertoire metrics across tumors. T-cell a)**
677 **density, b)** richness and **c)** clonality. **d)** Correlation between T-cell fraction, richness and
678 clonality. **e)** Distribution of most prevalent TCR clonotype.

679 **Figure 3. T-cell repertoire heterogeneity is observed across differentially growing**
680 **tumors. a)** Number of T-cell clonotypes in the primary tumor (red), metastases (blue) or


681 shared (purple). **b)** Shared T-cell clonotype proportions and **c)** frequencies between the
682 primary tumor and metastases.

683 **Figure 4. Evolution of synchronous metastases may be shaped by the T cell**
684 **repertoire. a)** Quantification of TCR repertoire heterogeneity across tumors by Jaccard
685 index (JI). **b)** Quantification of predicted neoantigen heterogeneity across tumors by JI.
686 **c)** Correlation between TCR repertoire JI and predicted neoantigen JI. **d)** Deconvolution
687 of immune components and T cell subpopulations by MethylCIBERSORT. **e)**
688 Correlation between T-cell richness and estimated CD8⁺ T-cell fraction. **f)** Correlation
689 between T-cell clonality and estimated CD8⁺ T-cell fraction.


690 **Figure 5. Methylated neoantigen burden is inversely correlated with T cell**
691 **repertoire metrics. a)** Total number of predicted neoantigens across tumors. **b)**
692 Comparison of predicted neoantigens between TCGA cohort and tumors in our study.
693 Correlation between ratio of methylated neoantigen coding mutations and T-cell **c)**
694 density, **d)** richness and **e)** clonality.

Figure 1


a



b



c



d

Nonsilent mutations (counts= 228)






Figure 2


a




b



c



d



e






Figure 3

a



b



c




Figure 4












a**b****c****d****e****f**

Figure 5

a**b****c****d****e****f**